The deal would add to Sanofi's portfolio the rare immunology disease drug Ayvakit/Ayvakyt, approved in the U.S. and the EU, and a promising advanced and early-stage immunology pipeline. Read more: https://pharma.economictimes.indiatimes.com/news/mergers-and-acquisitions/sanofis-9-billion-acquisition-of-blueprint-medicines-a-strategic-move-in-rare-disease-treatment/121570108